Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of DCR-PHXC in primary hyperoxaluria
NL-OMON49278Phase 2Active, not recruiting
- Sponsor
- Dicerna Pharmaceuticals, Inc.
- Start
- Aug 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Primary hyperoxaluria (PH), Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2) comparing DCR-PHXC with Placebo (2 arms). Primary endpoint: Responder rate for 24-hour urinary oxalate reduction. Started Aug 2020; status: active, not recruiting.
02
Drugs
nedosiran
03
Conditions
Primary hyperoxaluria (PH)Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)
Beyond the preview
Go deeper on NL-OMON49278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49278.